Frontiers in Cell and Developmental Biology (Oct 2022)
Editorial: Modeling neuromuscular diseases to determine molecular drivers of pathology and for drug discovery
- Alec S. T. Smith,
- Alec S. T. Smith,
- Megan L. McCain,
- Megan L. McCain,
- Mark Bothwell,
- Mark Bothwell,
- David L. Mack,
- David L. Mack,
- David L. Mack,
- David L. Mack
Affiliations
- Alec S. T. Smith
- Department of Physiology and Biophysics, University of Washington, Seattle, WA, United States
- Alec S. T. Smith
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, United States
- Megan L. McCain
- Department of Biomedical Engineering, USC Viterbi School of Engineering, University of Southern California, Los Angeles, CA, United States
- Megan L. McCain
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
- Mark Bothwell
- Department of Physiology and Biophysics, University of Washington, Seattle, WA, United States
- Mark Bothwell
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, United States
- David L. Mack
- Department of Physiology and Biophysics, University of Washington, Seattle, WA, United States
- David L. Mack
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, United States
- David L. Mack
- Department of Bioengineering, University of Washington, Seattle, WA, United States
- David L. Mack
- Department of Rehabilitation Medicine, University of Washington, Seattle, WA, United States
- DOI
- https://doi.org/10.3389/fcell.2022.1017356
- Journal volume & issue
-
Vol. 10
Abstract
No abstracts available.Keywords
- neuromuscular disease (NMD)
- disease modeling
- iPSC (induced pluripotent stem cell)
- cell line (C2C12)
- therapy screening
- in vitro versus in vivo
